An update from Organovo Holdings ( (ONVO) ) is now available.
On March 19, 2025, Organovo Holdings, Inc. announced a 1-for-12 reverse stock split of its common stock, effective March 20, 2025, to regain compliance with Nasdaq’s minimum bid price requirement. This move will reduce the number of outstanding shares from approximately 21.4 million to 1.8 million, while maintaining the current par value and authorized shares, and adjusting equity incentive plans proportionately.
More about Organovo Holdings
Organovo Holdings, Inc. is a clinical stage biotechnology company that focuses on developing novel treatment approaches for inflammatory bowel disease (IBD). The company utilizes proprietary technology to create three-dimensional (3D) human tissues that replicate key aspects of native human tissue, aiding in drug development.
YTD Price Performance: -8.41%
Average Trading Volume: 8,037,711
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $7.05M
For a thorough assessment of ONVO stock, go to TipRanks’ Stock Analysis page.